Combination therapies are also being explored, such as a phase II study combining semaglutide with the FXR agonist cilofexor and the ACC inhibitor firsocostat, which showed greater improvements in hepatic steatosis and metabolic biomarkers compared to semaglutide alone. Here, NR1H4 is linked to fatty liver disease.